ISSN: 2157-2526

バイオテロとバイオディフェンスのジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

インデックス付き
  • CAS ソース インデックス (CASSI)
  • 索引コペルニクス
  • Google スカラー
  • シェルパ・ロミオ
  • Jゲートを開く
  • Genamics JournalSeek
  • アカデミックキー
  • ジャーナル目次
  • 研究聖書
  • 中国国家知識基盤 (CNKI)
  • ウルリッヒの定期刊行物ディレクトリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • SWBオンラインカタログ
  • パブロン
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • ICMJE
このページをシェアする

抽象的な

AI-based scalable breast cancer screening solution in resource-constrained settings

Lakshmi Krishnan

Cancer of the breast is the most common cause of cancer-related deaths in India. Detecting breast cancer at early stages is critical for providing early treatment and thereby reducing disease morbidity and mortality. Mammography is the only screening method proved by randomized trials to reduce breast cancer mortality. However, it is less sensitive in women with dense breasts, and hence, its usage is limited in Asian countries where breast cancer is being increasingly detected in younger pre-menopausal women. Moreover, in India, where breast cancer screening is recommended at district hospitals (DHs), there are just 55 mammography machines at Government DHs to cater to 763 districts. Apart from increasing screening uptake at DHs, it is also necessary to make screening accessible at community health centres (CHCs). In a resource constrained setting, the cost of the equipment and high-skill requirement for interpretations makes mammography less affordable and feasible as a routine screening method. The more affordable clinical breast examination suffers from inconsistent results and late detection. Niramai’s Thermalytix™ is an AI-based solution that has demonstrated high sensitivity for screening breast cancers. This automated test is affordable, accessible, scalable for population-level screening and has already been used to screen over 30,000 women. However, loss to follow-up and risk perception in the asymptomatic population remains a barrier for large-scale screening programmes. This can be addressed by taking a holistic approach and combining screening of the top three cancers: breast, cervical, and oral cancers, along with other major noncommunicable diseases such as cardio-vascular disease, stroke, and diabetes at the CH